BLAINJECTIONINJECTABLE2 Generics Approved
Approved
Apr 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
21
Data completeness
6/8 — Strong
LANTUS (insulin glargine) by Sanofi. Approved for insulin analog [epc]. First approved in 2000.
Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LANTUS is a basal insulin analog (insulin glargine) administered by injection for managing type 1 and type 2 diabetes. It provides long-acting glycemic control by mimicking the body's basal insulin secretion. The drug is a cornerstone therapy in insulin regimens for patients requiring sustained glucose suppression.
$0.736BPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with high competitive pressure; commercial teams face market contraction and defensive positioning strategies.
Mechanism of Action
Pharmacologic Class:
Insulin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
Started Aug 2026
1,778 enrolled
Type 2 DiabetesCardiovascular Risk
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
Started Aug 2025
877 enrolled
Diabetes Mellitus, Type 1
Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS Glargine (G), United States (US)-Lantus®, and European Union (EU)-Lantus®
Started Oct 2024
114 enrolled
Healthy Participants
A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes
Started Apr 2024
412 enrolled
Diabetes, Type 2
A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)
Started Feb 2024
485 enrolled
Type 2 Diabetes
Worked on LANTUS at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.